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ORIGINAL INVESTIGATION
Alirocumab therapy in individuals with type 
2 diabetes mellitus and atherosclerotic 
cardiovascular disease: analysis of the ODYSSEY 
DM-DYSLIPIDEMIA and DM-INSULIN studies
Kausik K. Ray1*, Stefano Del Prato2, Dirk Müller‑Wieland3, Bertrand Cariou4, Helen M. Colhoun5, 
Francisco J. Tinahones6, Catherine Domenger7, Alexia Letierce8, Jonas Mandel9, Rita Samuel10, 
Maja Bujas‑Bobanovic11 and Lawrence A. Leiter12
Abstract 
Background: Individuals with diabetes often have high levels of atherogenic lipoproteins and cholesterol reflected 
by elevated low‑density lipoprotein cholesterol (LDL‑C), non‑high‑density lipoprotein cholesterol (non‑HDL‑C), 
apolipoprotein B (ApoB), and LDL particle number (LDL‑PN). The presence of atherosclerotic cardiovascular disease 
(ASCVD) increases the risk of future cardiovascular events. We evaluated the efficacy and safety of the proprotein 
convertase subtilisin/kexin type 9 (PCSK9) inhibitor, alirocumab, among individuals with type 2 diabetes (T2DM), high 
LDL‑C or non‑HDL‑C, and established ASCVD receiving maximally tolerated statin in ODYSSEY DM‑DYSLIPIDEMIA 
(NCT02642159) and DM‑INSULIN (NCT02585778).
Methods: In DM‑DYSLIPIDEMIA, individuals with T2DM and mixed dyslipidemia (non‑HDL‑C ≥ 100 mg/dL; 
n = 413) were randomized to open‑label alirocumab 75 mg every 2 weeks (Q2W) or usual care (UC) for 24 weeks, 
with UC options selected before stratified randomization. In DM‑INSULIN, insulin‑treated individuals with T2DM 
(LDL‑C ≥ 70 mg/dL; n = 441) were randomized in a double‑blind fashion to alirocumab 75 mg Q2W or placebo for 
24 weeks. Study participants also had a glycated hemoglobin < 9% (DM‑DYSLIPIDEMIA) or < 10% (DM‑INSULIN). Ali‑
rocumab dose was increased to 150 mg Q2W at week 12 if week 8 LDL‑C was ≥ 70 mg/dL (DM‑INSULIN) or non‑HDL‑
C was ≥ 100 mg/dL (DM‑DYSLIPIDEMIA). Lipid reductions and safety were assessed in patients with ASCVD from these 
studies.
Results: This analysis included 142 DM‑DYSLIPIDEMIA and 177 DM‑INSULIN participants with ASCVD, including 95.1% 
and 86.4% with coronary heart disease, and 32.4% and 49.7% with microvascular diabetes complications, respectively. 
At week 24, alirocumab significantly reduced LDL‑C, non‑HDL‑C, ApoB, and LDL‑PN from baseline versus control. This 
translated into a greater proportion of individuals achieving non‑HDL‑C < 100 mg/dL (64.6% alirocumab/23.8% UC 
[DM‑DYSLIPIDEMIA]; 65.4% alirocumab/14.9% placebo [DM‑INSULIN]) and ApoB < 80 mg/dL (75.1% alirocumab/35.4% 
UC and 76.8% alirocumab/24.8% placebo, respectively) versus control at week 24 (all P < 0.0001). In pooling these 
studies, 66.4% (alirocumab) and 67.0% (control) of individuals reported treatment‑emergent adverse events. The 
adverse event pattern was similar with alirocumab versus controls.
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/




1 Imperial Centre for Cardiovascular Disease Prevention, Department 
of Primary Care and Public Health, Imperial College, Kensington, 
London SW7 2AZ, UK
Full list of author information is available at the end of the article
Page 2 of 10Ray et al. Cardiovasc Diabetol          (2019) 18:149 
Background
The leading cause of morbidity and mortality for indi-
viduals with diabetes is atherosclerotic cardiovascular 
disease (ASCVD). ASCVD may present as acute throm-
botic manifestations of vascular disease, such as acute 
coronary syndrome (ACS), myocardial infarction (MI), 
unstable angina, stroke, and transient ischemic attack, 
or as occlusive manifestations of atherosclerotic vascu-
lar disease, such as stable angina and claudication [1, 2]. 
Atherogenic dyslipidemia is often observed in individu-
als with type 2 diabetes mellitus (T2DM), contributing 
to a higher risk of ASCVD [3]. This atherogenic dyslipi-
demia consists of an excess of atherogenic apolipoprotein 
B (ApoB)-containing lipoproteins, which is reflected by 
higher circulating ApoB, non-high-density lipoprotein 
cholesterol (non-HDL-C), and low-density lipoprotein 
particle number (LDL-PN) [1, 3, 4]. In addition, triglycer-
ides are elevated and levels of HDL-C are low [3]. There-
fore, lowering atherogenic cholesterol cargo is a major 
aim in many guidelines.
The 2019 American Diabetes Association (ADA) 
and the 2019 European Society of Cardiology (ESC)/
European Atherosclerosis Society (EAS) guidelines rec-
ommend additional low-density lipoprotein-lowering 
therapy, such as ezetimibe or a proprotein convertase 
subtilisin/kexin type 9 (PCSK9) inhibitor, for patients 
who have diabetes and ASCVD if low-density lipoprotein 
cholesterol (LDL-C) goals are not met on the maximally 
tolerated statin dose [5, 6]. In the 2018 US cholesterol 
guidelines from the American College of Cardiology, 
American Heart Association, 2019 ESC/EAS guidelines, 
and others, individuals with clinical ASCVD are catego-
rized as being at very high risk for cardiovascular (CV) 
events if they have additional risk factors, including dia-
betes and elevated LDL-C. Very high risk individuals who 
are on maximally tolerated LDL-C-lowering therapy with 
an LDL-C level of ≥ 70 mg/dL (≥ 1.8 mmol/L), or have a 
non-HDL-C level of ≥ 100  mg/dL (≥ 2.6  mmol/L), may 
add a PCSK9 inhibitor following a discussion with their 
clinician about the overall benefit, safety, and cost [2, 6]. 
The ODYSSEY OUTCOMES trial investigated the role 
of the PCSK9 inhibitor, alirocumab, in improving CV 
outcomes after ACS in patients on high-intensity statin 
therapy [7]. Results demonstrated that the risk of recur-
rent ischemic CV events was lower among those who 
were treated with alirocumab than placebo in this patient 
population. Alirocumab has further been assessed in two 
dedicated randomized studies in individuals with dia-
betes and hypercholesterolemia on maximally tolerated 
statin and either established ASCVD or additional CV 
risk factors: ODYSSEY DM-DYSLIPIDEMIA and DM-
INSULIN [4, 8]. In this analysis, we evaluated the efficacy 
and safety of alirocumab versus control among individu-
als with T2DM, established ASCVD, and elevated non-
HDL-C or LDL-C despite receiving maximally tolerated 
statin in the DM-DYSLIPIDEMIA and DM-INSULIN 
studies.
Methods
This analysis included individuals with established 
ASCVD receiving maximally tolerated statin who were 
enrolled in the DM-DYSLIPIDEMIA and DM-INSU-
LIN studies. ASCVD was defined as coronary heart dis-
ease (CHD; acute and silent MI, and unstable angina), 
ischemic stroke, or peripheral artery disease (PAD).
The DM-DYSLIPIDEMIA (NCT02642159) is a Phase 
IIIb/IV randomized, open-label, parallel group, mul-
ticenter, multinational clinical trial [9]. Individuals 
(n = 413) aged ≥ 18  years with T2DM and mixed dys-
lipidemia whose non-HDL-C level was not adequately 
controlled (≥ 100  mg/dL [> 2.59  mmol/L]) despite sta-
ble maximally tolerated statin dose for ≥ 4  weeks prior 
to screening visit, without other lipid-lowering thera-
pies (LLTs), and who had either a documented his-
tory of ASCVD and/or at least one additional CV risk 
factor were included. Mixed dyslipidemia was defined 
as non-HDL-C ≥ 100  mg/dL (≥ 2.59  mmol/L) and tri-
glycerides ≥ 150  mg/dL (≥ 1.70  mmol/L) and < 500  mg/
dL (< 5.65  mmol/L). Study participants were also 
required to have a glycated hemoglobin (HbA1c) level 
of < 9% (74.9  mmol/mol). Eligible individuals were ran-
domized to open-label alirocumab 75  mg (with blinded 
dose increase to 150  mg at week 12 if week 8 non-
HDL-C was ≥ 100  mg/dL [≥ 2.59  mmol/L]) or usual 
care (UC) every 2 weeks for 24 weeks, with UC options 
selected before stratified randomization based on the 
Conclusions: Among individuals with T2DM and ASCVD who had high non‑HDL‑C/LDL‑C levels despite maximally 
tolerated statin, alirocumab significantly reduced atherogenic cholesterol and LDL‑PN versus control. Alirocumab was 
generally well tolerated.
Trial registration Clinicaltrials.gov. NCT02642159. Registered 30 December 2015 and Clinicaltrials.gov. NCT02585778. 
Registered 23 October 2015
Keywords: Alirocumab, Atherosclerotic cardiovascular disease, Type 2 diabetes mellitus, Low‑density lipoprotein 
cholesterol, Dyslipidemia
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investigator’s preference for each participant. The fol-
lowing five UC options were included in the study: con-
tinued use of maximally tolerated statin therapy with 
no additional LLT, fenofibrate, ezetimibe, omega-3 fatty 
acid, and nicotinic acid, reflecting variability in regional 
practice and therapeutic options available at the time 
the study was conducted. Safety was assessed through 
adverse events, laboratory parameters and vital signs. 
Treatment-emergent adverse events were defined as any 
event that developed, worsened or became serious dur-
ing the period from first to last open-label dose of ali-
rocumab plus 70 days (if randomized to alirocumab) or, if 
randomized to UC, 70 days after the last UC treatment or 
study day 225 (whichever came first).
In the DM-INSULIN (NCT02585778) phase IIIb, 
randomized, double-blind, placebo controlled, paral-
lel group, multicenter trial, insulin-treated individuals 
aged ≥ 18  years with T2DM (n = 441) or type 1 diabe-
tes mellitus (T1DM; n = 76) diagnosed ≥ 1  year prior 
to screening, and who had either a documented his-
tory of ASCVD and/or at least one additional CV risk 
factor were randomized in a 2:1 double-blind fashion 
to alirocumab or placebo for 24  weeks [4]. Study par-
ticipants were also required to have a HbA1c level < 10% 
(86 mmol/mol). Alirocumab-treated individuals received 
75 mg every 2 weeks (Q2W), with blinded dose increase 
to 150 mg Q2W at week 12 if week 8 LDL-C was ≥ 70 mg/
dL (≥ 1.81  mmol/L). Statins and other LLTs remained 
stable throughout the duration of the study. Primary 
safety endpoints were assessed up to week 32 through 
treatment-emergent adverse events (TEAE) reports, 
laboratory data, product complaints, and vital signs. Par-
ticipants with T1DM were not included in the current 
analysis due to the low number of individuals with estab-
lished ASCVD in this group (alirocumab: n = 11; placebo: 
n = 5).
Due to the substantial differences in the patient popu-
lations from DM-DYSLIPIDEMIA and DM-INSULIN, as 
well as the methodological differences between the two 
studies, efficacy was analyzed separately. The efficacy 
analysis included week 24 percentage reduction from 
baseline in non-HDL-C, calculated LDL-C, ApoB, triglyc-
eride-rich lipoproteins (TGRL), and LDL-PN; the per-
centage of individuals achieving non-HDL-C < 100  mg/
dL (< 2.59 mmol/L), LDL-C < 70 mg/dL (< 1.81 mmol/L), 
and ApoB < 80 mg/dL at week 24. TGRL was defined as 
non-HDL-C minus measured LDL-C if measured LDL-C 
not missing; non-HDL-C minus calculated LDL-C if 
measured LDL-C missing and calculated LDL-C not 
missing, using fasting samples first, or if fasting sam-
ple missing using non-fasting measurements. Efficacy 
data were analyzed with an intention-to-treat approach, 
including all randomized individuals with a non-HDL-C 
(DM-DYSLIPIDEMIA) or LDL-C (DM-INSULIN) value 
at baseline and at least one value post-baseline up to 
week 24. Safety data were pooled due to the small sample 
size, however separate adverse event outcomes are also 
reported.
Statistical analysis
This was a post hoc analysis with similar statistical meth-
ods to those used in the primary DM-DYSLIPIDEMIA 
and DM-INSULIN studies [4, 8]. Percent changes from 
baseline in non-HDL-C, HDL-C, LDL-C, Apo-B and 
LDL-PN at week 24 were derived and compared between 
treatment groups using a mixed-effects model with 
repeated measures (MMRM), which accounts for missing 
data and utilizes every lipid values at week 0, 8, 12, 20 and 
24. For TGRL, as normal distribution assumption wasn’t 
satisfied, their percent changes from baseline were esti-
mated by robust regressions preceded by multiple impu-
tations to handle missing data: combined estimates for 
means and standard errors (SE) are obtained by combin-
ing adjusted means and SE from robust regression model 
analyses of the different imputed datasets, using Rubin 
formulae.
The proportion of individuals achieving the different 
goals at week 24 were analyzed by multiple imputation 
followed by a logistic regression: the logistic regres-
sion included the treatment group and the UC stratum 
(for DM-DYSLIPIDEMIA) as main effects and the cor-
responding baseline value as covariate. Missing values 
were addressed using a multiple imputation approach 
and the logistic regressions were repeatedly performed in 
the datasets containing both observed and imputed lipid 
values and combined using Rubin formulae to allow for 
the treatment comparison. Analyses were in the intent-
to-treat populations and for DM-DYSLIPIDEMIA, analy-
ses are adjusted on the UC stratum. Descriptive analyses 
were performed for baseline, other efficacy, and safety 
analyses.
Results
This analysis included 142 individuals from the DM-
DYSLIPIDEMIA trial and 177 individuals from the DM-
INSULIN trial, all of whom had established ASCVD and 
T2DM (Table  1). Overall, 93.7% of pooled individuals 
from DM-DYSLIPIDEMIA and 89.3% of individuals from 
DM-INSULIN had a history of hypertension, and 18.3% 
and 28.2% had chronic kidney disease on top of ASCVD, 
respectively. In total, 13.4% of pooled individuals from 
DM-DYSLIPIDEMIA and 20.3% of individuals from DM-
INSULIN demonstrated a history of ischemic stroke; 
7.0% and 10.7% had PAD, respectively; 95.1% and 86.4% 
had CHD, respectively; and 32.4% and 49.7% had micro-
vascular diabetes complications, respectively.
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At baseline, pooled mean (standard deviation [SD]) 
non-HDL-C levels were 156.6 (46.6) mg/dL (4.06 [1.21] 
mmol/L) in DM-DYSLIPIDEMIA and 144.2 (46.2) mg/
dL [3.73 (1.20) mmol/L] in DM-INSULIN; pooled LDL-C 
levels were 108.7 (45.4) mg/dL [2.81 (1.18) mmol/L] and 
108.7 (39.1) mg/dL [2.82 (1.01) mmol/L], respectively; 
and pooled ApoB levels were 103.4 (26.9) mg/dL [2.67 
(0.7) mmol/L] and 97.2 (27.6) mg/dL [2.51 (0.7) mmol/L]. 
The majority of individuals in both trials had diabe-
tes for > 10  years, with a mean (SD) of 13.7 (8.8)  years 
Table 1 Baseline characteristics (randomized population)
Apo apolipoprotein, BMI body mass index, CHD coronary heart disease, CKD chronic kidney disease, DPP-4 dipeptidyl peptidase-4, GLP-1 glucagon-like peptide-1, 
GLT glucose-lowering treatment, FPG fasting plasma glucose, HbA1c glycated hemoglobin, HDL-C high-density lipoprotein cholesterol, HTN hypertension, LDL-C low-
density lipoprotein cholesterol, LDL-PN low-density lipoprotein particle number, LLT lipid-lowering therapy, MI myocardial infarction, PAD peripheral artery disease, SD 
standard deviation, SGLT2 sodium glucose cotransporter 2
a Diagnosis by invasive/non-invasive testing
b Includes patients with established HTN on anti-HTN medication
c Defined as estimated glomerular filtration rate 15–60 mL/min/1.73 m2
d Defined as microalbuminuria, macroalbuminuria, retinopathy, and/or CKD
e LLT other than statins were not allowed per protocol in DM DYSLIPIDEMIA
f One individual in the placebo group was not receiving insulin at the time of randomization and remained without insulin treatment for the duration of the study
DM-DYSLIPIDEMIA DM-INSULIN
Alirocumab (n = 95) UC (n = 47) Alirocumab (n = 119) Placebo (n = 58)
Age, years, mean (SD) 64.9 (9.1) 65.4 (8.1) 66.2 (8.7) 64.9 (8.9)
Gender, male, n (%) 65 (68.4) 31 (66.0) 79 (66.4) 32 (55.2)
BMI, kg/m2, mean (SD) 33.0 (5.4) 32.7 (4.9) 32.6 (4.5) 33.4 (5.8)
CHD, n (%) 90 (94.7) 45 (95.7) 102 (85.7) 51 (87.9)
 Acute MI 43 (45.3) 20 (42.6) 59 (49.6) 18 (31.0)
 Silent MI 5 (5.3) 1 (2.1) 4 (3.4) 4 (6.9)
 Unstable angina 15 (15.8) 9 (19.1) 15 (12.6) 4 (6.9)
 Coronary revascularization 77 (81.1) 35 (74.5) 80 (67.2) 37 (63.8)
 Other clinically significant  CHDa 20 (21.1) 14 (29.8) 31 (26.1) 15 (25.9)
Ischemic stroke, n (%) 14 (14.7) 5 (10.6) 27 (22.7) 9 (15.5)
PAD, n (%) 6 (6.3) 4 (8.5) 13 (10.9) 6 (10.3)
HTNb, n (%) 89 (93.7) 44 (93.6) 105 (88.2) 53 (91.4)
CKDc, n (%) 15 (15.8) 11 (23.4) 37 (31.1) 13 (22.4)
Diabetes target organ  damaged, n (%) 31 (32.6) 15 (31.9) 60 (50.4) 28 (48.3)
Statin, n (%) 80 (84.2) 41 (87.2) 92 (77.3) 42 (72.4)
 Low intensity 6 (7.5) 0 3 (3.3) 1 (2.4)
 Moderate intensity 21 (26.3) 20 (48.8) 46 (50.0) 24 (57.1)
 High intensity 53 (66.3) 21 (51.2) 43 (46.7) 16 (38.1)
LLT other than  statine, n (%) 0 2 (4.3) 34 (28.6) 11 (19.0)
HbA1c, %, mean (SD) 7.0 (0.8) 7.2 (0.8) 7.5 (0.9) 7.4 (1.0)
FPG, mg/dL [mmol/L], mean (SD) 144.1 (39.3) [8.0 (2.2)] 152.6 (41.7) [8.5 (2.3)] 162.6 (52.5) [9.0 (2.9)] 146.7 (45.2) [8.1 (2.5)]
Insulin, n (%) 40 (42.1) 19 (40.4) 119 (100) 57 (98.3)f
Non‑insulin GLT, n (%)
 Biguanides 72 (75.8) 34 (72.3) 57 (47.9) 33 (56.9)
 Sulfonylureas 29 (30.5) 18 (38.3) 11 (9.2) 7 (12.1)
 DPP‑4 inhibitor 12 (12.6) 8 (17.0) 21 (17.6) 7 (12.1)
 GLP‑1 receptor agonist 16 (16.8) 6 (12.8) 11 (9.2) 8 (13.8)
 SGLT2 inhibitor 10 (10.5) 5 (10.6) 10 (8.4) 11 (19.0)
Lipids, mg/dL [mmol/L], mean (SD)
 Non‑HDL‑C 156.5 (48.4) [4.05 (1.26)] 156.8 (43.3) [4.06 (1.12)] 142.8 (41.5) [3.70 (1.08)] 147.0 (54.9) [3.81 (1.42)]
 LDL‑C 108.3 (46.3) [2.81 (1.20)] 109.4 (44.0) [2.83 (1.14)] 107.2 (35.1) [2.78 (0.91)] 111.9 (46.4) [2.90 (1.20)]
 ApoB 103.0 (26.7) 104.3 (27.8) 96.4 (25.1) 98.7 (32.0)
 LDL‑PN, nmol/L, mean (SD) 1400.2 (489.8) 1437.4 (479.4) 1339.5 (408.5) 1425.0 (467.9)
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in alirocumab-treated individuals and 13.0 (9.7)  years 
for UC individuals in DM DYSLIPIDEMIA. In DM-
INSULIN, the mean (SD) duration of diabetes was 17.4 
(8.3)  years for alirocumab and 18.3 (9.2)  years for pla-
cebo. Mean baseline HbA1c levels were 7.0% and 7.2% 
for alirocumab and placebo, respectively in DM-DYSLIP-
IDEMIA, and 7.5% for both alirocumab and placebo in 
DM-INSULIN. In DM-DYSLIPIDEMIA, 41.5% of pooled 
individuals were treated with insulin while 99.4% of indi-
viduals from DM-INSULIN received insulin therapy. For 
both studies, non-insulin glucose-lowering treatment 
included biguanides, sulfonylureas, dipeptidyl pepti-
dase-4 inhibitors, glucagon-like peptide-1 receptor ago-
nists, and sodium glucose contransporter-2 inhibitors.
Efficacy
Alirocumab significantly reduced non-HDL-C, LDL-
C, ApoB, and LDL-PN from baseline to week 24 versus 
controls among individuals with T2DM and ASCVD in 
the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN 
studies (Fig.  1). The percentage change from baseline 
to week 24 in LDL-PN was − 42.6% for alirocumab ver-
sus − 7.6% for UC in DM-DYSLIPIDEMIA and − 38.5% 
for alirocumab versus 2.3% for placebo (Fig.  1). The LS 
mean difference (standard error [SE]) versus control was 
− 35.0% (4.4) (95% confidence interval [CI] − 43.7 to 
− 26.3; P < 0.0001) for DM-DYSLIPIDEMIA and − 40.8% 
(3.9) (95% CI − 48.4 to − 33.2; P < 0.0001) for DM-INSU-
LIN. Notably, the percentage change from baseline to 
week 24 in TGRL was − 28.3% (3.6) for alirocumab versus 
− 18.7% (5.1) for UC in DM-DYSLIPIDEMIA (adjusted 
mean difference [SE] − 9.6 [6.3] 95% confidence inter-
val [CI] − 21.9 to 2.7, P = 0.13) and − 19.1% (3.5) for ali-
rocumab versus − 2.1% (5.1) for placebo in DM-INSULIN 
(adjusted mean difference [SE] − 17.0 [6.2] 95% CI − 29.1 
to − 4.9, P = 0.01). At week 24, a significantly greater pro-
portion of individuals achieved non-HDL-C < 100 mg/dL 
(< 2.59 mmol/L), LDL-C < 70 mg/dL (< 1.81 mmol/L), and 
ApoB < 80 mg/dL versus control (all P < 0.0001; Fig. 2).
Safety
In total, 66.7% (alirocumab) and 67.3% (control) of indi-
viduals reported TEAEs (Table  2). Treatment emergent 
serious adverse events (SAEs) were reported in 9.5% (ali-
rocumab) versus 8.8% (UC) of individuals in DM-DYS-
LIPIDEMIA and 9.0% (alirocumab) versus 9.4% (placebo) 
of individuals in DM-INSULIN. The adverse event pat-
tern was similar in both pooled alirocumab and control 
Fig. 1 Percentage change from baseline to week 24 in non‑HDL‑C, LDL‑C, ApoB, LDL‑PN (ITT). Apo apolipoprotein, HDL-C high‑density lipoprotein 
cholesterol, ITT intent‑to‑treat, LDL-C low‑density lipoprotein cholesterol, LDL-PN low‑density lipoprotein particle number, LS least‑squares, SE 
standard error, UC usual care
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groups. Results for adverse events for the two treatment 
arms in each study may be seen in Table 3.
Mean (SD) levels of HbA1c were similar in each treat-
ment group at baseline (alirocumab: 7.3 [0.9]%; control: 
7.3 [0.9]%) and week 24 (alirocumab: 7.6 [1.2]%; control: 
7.5 [1.2]%; safety analysis). Fasting plasma glucose lev-
els were also similar regardless of treatment allocation 
at baseline (alirocumab: 154.2 [47.9]  mg/dL, 8.6 [2.7] 
mmol/L; control: 149.5 [43.7] mg/dL, 8.3 [2.4] mmol/L) 
and at week 24 (alirocumab: 164.7 [54.9] mg/dL, 9.1 [3.0] 




The participants included in this analysis from the DM-
DYSLIPIDEMIA and DM INSULIN trials had both 
prior ASCVD and T2DM, and represent a population 
with a very high risk of CV events for which a target 
LDL-C < 70  mg/dL and non-HDL-C < 100  mg/dL were 
generally recommended at the time of study implemen-
tation [10, 11]. In our study population, statins at maxi-
mally tolerated doses were largely insufficient to achieve 
guideline-recommended lipid goals and thus it represents 
a group with high residual risk and an unmet therapeu-
tic need. In the present analysis, significant reductions 
in LDL-C, non-HDL-C, and Apo B were observed with 
alirocumab versus controls, which is consistent with the 
results in the overall trial populations from the primary 
DM-DYSLIPIDEMIA and DM-INSULIN studies. Ali-
rocumab treatment resulted in significant LDL-C reduc-
tions from baseline to week 24 compared with either UC 
or placebo (− 43.0% and − 49.0%, respectively; P < 0.0001) 
on background maximally tolerated statin therapy [4, 8]. 
Furthermore, alirocumab also significantly reduced non-
HDL-C and ApoB at week 24 versus control, which bet-
ter predict total atherogenic burden in this population, 
and results were consistent with the results of the pri-
mary studies [4, 8]. Finally, levels of low-density lipopro-
tein particle (LDL-P), which may more closely align with 
CV risk than LDL-C in diabetes, were also significantly 
reduced with alirocumab therapy.
This post hoc analysis confirmed similar adverse event 
patterns in alirocumab-treated individuals and controls 
already reported in other studies. In both studies, ali-
rocumab was generally well tolerated, with comparable 
rates of TEAEs between alirocumab and UC or placebo. 
The overall incidence of injection-site reactions for both 
primary studies was low, with no greater incidence seen 
in alirocumab-treated individuals [4, 8]. However, in the 
overall alirocumab trial population, including both indi-
viduals with and without diabetes, injection-site reac-
tions were found at a higher frequency with alirocumab 
compared with controls [8, 12]. In a real-world analysis 
Fig. 2 Percentage of individuals achieving non‑HDL‑C, LDL‑C, and ApoB targets at week 24 (ITT). Non‑HDL‑C: 100 mg/dL = 2.59 mmol/L; LDL‑C: 
70 mg/dL = 1.81 mmol/L. Apo apolipoprotein, HDL-C high‑density lipoprotein cholesterol, ITT intent‑to‑treat, LDL-C low‑density lipoprotein 
cholesterol, UC usual care
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of three datasets from a hospital registry (n = 164), and 
two pharmacovigilance databases, Lareb (n = 149) and 
VigiLyze (n = 15,554), PCSK9 inhibitors were found to be 
well tolerated with an overall safety profile comparable 
to currently available randomized clinical trials [13]. The 
most common adverse events included influenza-like ill-
ness, nasopharyngitis, myalgia, and injection-site reac-
tions, all of which resolved over time. Furthermore, while 
the benefit of PCSK9 inhibitors is primarily ascribed to 
their LDL-C reducing activity, data suggest that they may 
also influence platelet function and blood coagulation 
[14].
CV events and outcomes
Long-term CV outcome studies have shown that 
PCSK9 inhibitors reduce CV event rates similarly in 
individuals with and without T2DM and prior CV 
disease or recent acute coronary syndrome [15, 16]. 
However, absolute risk is higher among those with 
diabetes and established ASCVD and therefore these 
patients are expected to derive greater absolute ben-
efits from further LLT. In the FOURIER trial, patients 
with diabetes and a baseline LDL-C level of around 
90  mg/dL had a 5-point major adverse CV event rate 
of 17.1%, which decreased to 14.4% by reducing LDL-C 
to around 30  mg/dL [17]. The latter event rate is only 
marginally higher than the 13.0% event rate among 
patients without diabetes, stable ASCVD, and LDL-C 
of around 90  mg/dL, highlighting the important role 
more intensive LDL-C lowering can have in mitigat-
ing the excess CV risk in high-risk states. In addition, 
a reduction in LDL-C levels to target concentrations of 
25.1  mg/dL (0.65  mmol/L)–50.3  mg/dL (1.3  mmol/L) 
has been proposed to reduce CV events in patients 
with a recent ACS and diabetes [15]. In an analy-
sis of the ODYSSEY OUTCOMES trial, the effect of 
Table 2 Safety summary (pool of  DM-INSULIN 
and DM-DYSLIPIDEMIA; safety population)
SAE serious adverse event, TEAE treatment-emergent adverse event
n (%) Alirocumab (n = 213) Control (n = 104)
TEAEs 142 (66.7) 70 (67.3)
Treatment‑emergent SAEs 28 (13.1) 10 (9.6)
TEAEs leading to death 1 (0.5) 1 (1.0)
TEAEs occurring in ≥ 2% of individuals by preferred term
 Urinary tract infection 8 (3.8) 6 (5.8)
 Diarrhea 8 (3.8) 6 (5.8)
 Hypertension 8 (3.8) 4 (3.8)
 Influenza 7 (3.3) 4 (3.8)
 Headache 7 (3.3) 1 (1.0)
 Musculoskeletal pain 7 (3.3) 3 (2.9)
 Nasopharyngitis 6 (2.8) 5 (4.8)
 Back pain 6 (2.8) 2 (1.9)
 Dizziness 6 (2.8) 3 (2.9)
 Fatigue 5 (2.3) 3 (2.9)
 Cataract 5 (2.3) 1 (1.0)
 Myalgia 5 (2.3) 1 (1.0)
 Nausea 4 (1.9) 3 (2.9)
 Pain in extremity 4 (1.9) 3 (2.9)
 Arthralgia 3 (1.4) 3 (2.9)
 Bronchitis 3 (1.4) 3 (2.9)
 Hypotension 2 (0.9) 3 (2.9)
 Cough 1 (0.5) 3 (2.9)
 Hyperglycemia 0 (0.0) 3 (2.9)
Table 3 Safety summary (randomized population)
DM-DYSLIPIDEMIA DM-INSULIN
Alirocumab (n = 95) UC (n = 47) Alirocumab (n = 118) Placebo (n = 57)
TEAEs occurring in ≥ 2% of individuals by preferred term, n (%)
 Urinary tract infection 5 (5.3) 2 (4.3) 3 (2.5) 4 (7.0)
 Diarrhea 5 (5.3) 3 (6.4) 3 (2.5) 3 (5.3)
 Hypertension 3 (3.2) 1 (2.1) 5 (4.2) 3 (5.3)
 Influenza 3 (3.2) 3 (6.4) 4 (3.4) 1 (1.8)
 Musculoskeletal pain 4 (4.2) 1 (2.1) 3 (2.5) 2 (3.5)
 Back pain 2 (2.1) 2 (4.3) 4 (3.4) 0
 Dizziness 3 (3.2) 1 (2.1) 3 (2.5) 2 (3.5)
 Fatigue 2 (2.1) 2 (4.3) 3 (2.5) 1 (1.8)
 Cataract 1 (1.1) 1 (2.1) 4 (3.4) 0
 Myalgia 2 (2.1) 1 (2.1) 3 (2.5) 0
 Nausea 2 (2.1) 1 (2.1) 2 (1.7) 2 (3.5)
 Pain in extremity 2 (2.1) 2 (4.3) 2 (1.7) 1 (1.8)
 Bronchitis 0 2 (4.3) 3 (2.5) 1 (1.8)
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alirocumab on CV outcomes was assessed by baseline 
glycemic status (27.7% were patients with normoglyce-
mia, 28.8% with diabetes, and 43.6% with pre-diabetes). 
Results demonstrated that after a recent ACS, treat-
ment with alirocumab targeting the above-mentioned 
LDL-C concentrations produces about twice the abso-
lute reduction in CV events among patients with dia-
betes as in those without diabetes [15]. Furthermore, it 
has recently been reported that alirocumab on top of 
intensive statin therapy potentially reduces death after 
ACS, particularly in treatments for ≥ 3  years, if base-
line LDL-C is ≥ 100 mg/dL, or if achieved LDL-C is low 
[18].
Current treatment guidelines recommend that LDL-C 
targets are set according to an individual’s CV risk. 
Individuals with T2DM and prior ASCVD are classi-
fied as being at extreme risk by the American Asso-
ciation of Clinical Endocrinologists (AACE), who 
recommend LDL-C targets of < 55  mg/dL, non-HDL-C 
targets of < 80  mg/dL, and ApoB targets of <  70  mg/dL 
for this patient population [19]. In addition, the AACE 
recommends the consideration of PCSK9 inhibitors in 
individuals with clinical CV disease who are unable to 
reach LDL-C or non-HDL-C goals with maximally tol-
erated statin therapy [19]. The published data from the 
FOURIER and ODYSSEY OUTCOMES trials further 
support this assertion; however, these more aggressive 
lipid targets have not been adopted by all guidelines to 
date. It is also important to note the influence that certain 
diabetic medications may have on PCSK9 expression. 
Liraglutide, a once-daily glucagon-like peptide-1 (GLP-
1) agonist, was found to suppress PCSK9 expression via 
a hepatocyte nuclear factor 1 alpha (HNF1α)-dependent 
mechanism in the human hepatoma cell line, HepG2 [20]. 
In this analysis, between 9 and 17% of patients received a 
GLP-1 agonist; however, it would not be appropriate to 
speculate the effects this may exert on the results.
It is noteworthy that in DM-DYSLIPIDEMIA, ali-
rocumab was superior to moderate-dose fish oils and 
fenofibrate in improving the atherogenic lipid profile [4]. 
Furthermore, results from the ACCORD-LIPID study 
demonstrated that combination therapy with fenofibrate 
and simvastatin did not significantly reduce CV event 
rates compared with statin monotherapy in patients with 
T2DM [21]. Ongoing trials, including the CVOT PROM-
INENT (NCT03071692) study are further investigating 
the use of fibrates in this patient population. This is clini-
cally relevant as fish oil and fenofibrate are considered by 
some as therapeutic options after statins in patients with 
mixed dyslipidemia. With that said, high dose eicosap-
entaenoic acid in the REDUCE-IT trial did reduce CV 
events despite achieving only modest reductions in tri-
glycerides and ApoB [22]. The reasons for this are unclear 
but could include beneficial pleiotropic effects beyond 
the change in atherogenic particle number.
Analysis of DM-DYSLIPIDEMIA and DM-INSULIN
DM-DYSLIPIDEMIA and DM-INSULIN were separate 
trials with different study designs (one versus UC and 
the other versus placebo); however, both studies were 
conducted exclusively in patients with diabetes. While 
patients in the DM-DYSLIPIDEMIA trial were enrolled 
because of elevated non-HDL-C, those in DM-INSU-
LIN were enrolled only based on elevated LDL-C. In 
DM-DYSLIPIDEMIA, alirocumab significantly reduced 
non-HDL-C (the primary endpoint) and LDL-C versus 
UC (P < 0.0001) [4]. In DM-INSULIN, alirocumab treat-
ment resulted in significant LDL-C reductions compared 
with placebo (P < 0.0001) [8]. As the study designs were 
different, we presented our analyses separately for each 
trial. However, it is worth noting that patients in the DM-
INSULIN trial had similar ApoB and LDL-P levels to 
those patients in the DM-DYSLIPIDEMIA trial. Further-
more, insulin therapy is often the end stage of glucose-
lowering medication intensification and the observation 
that patients on insulin had high levels of atherogenic 
lipoproteins only serves to reinforce the high CV risk of 
this patient population.
One major rationale for evaluating the subgroups with 
ASCVD in DM-DYSLIPIDEMIA and DM-INSULIN is 
because both studies investigated patients with increased 
levels of TGRL (non-HDL-C minus LDL-C). The aver-
age baseline level of TGRL was approximately 34  mg/
dL and 48  mg/dL in DM-INSULIN and DM-DYSLIPI-
DEMIA, respectively [4, 8]. These studies therefore rep-
resent a different diabetic patient population than those 
included in the FOURIER and ODYSSEY OUTCOMES 
trials, with broader eligibility criteria regarding the type 
of CV disease. In both of these clinical outcomes trials, 
non-HDL-C levels were ≤ 125  mg/dL and TGRL levels 
were < 32 mg/dL [7, 16].
Conclusion
In summary, among very high risk individuals with 
T2DM and ASCVD who had elevated non-HDL-C 
(DM-DYSLIPIDEMIA) or LDL-C (DM-INSULIN) lev-
els despite maximally tolerated statins, alirocumab sig-
nificantly reduced atherogenic cholesterol and improved 
achievement of LDL-C, non-HDL-C, and ApoB goals 
versus controls.
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